Prognostic Factors among Patients with Resected Non-Adenocarcinoma of the Lung

Abstract

<b><i>Introduction:</i></b> Few studies have investigated the prognostic factors for non-adenocarcinoma of the lung. We retrospectively evaluated the prognostic factors on the basis of histological type of non-adenocarcinoma of the lung treated by pulmonary resection. <b><i>Methods:</i></b> We enrolled 266 patients with non-adenocarcinoma of the lung in this retrospective study: 196 with squamous cell carcinoma (SCC) and 70 with non-SCC. <b><i>Results:</i></b> Relapse-free survival (RFS) did not differ significantly between SCC and non-SCC patients (<i>p</i> = 0.33). For SCC patients, RFS differed significantly between patients who underwent wedge resection and non-wedge resection (<i>p</i> &lt; 0.01) and between patients with Clavien-Dindo grade ≥3a and 0–2 postoperative complications (<i>p</i> &lt; 0.01). For non-SCC patients, RFS rates were significantly different in the groups divided at neutrophil-to-lymphocyte ratio = 2.40 (<i>p</i> = 0.02), maximum standardized uptake value (SUV_max) = 8.39 (<i>p</i> &lt; 0.01), between patients with pathological stage (pStage) 0–I and with pStage more than II (<i>p</i> &lt; 0.01). For SCC patients, male sex (<i>p</i> = 0.04), wedge resection (<i>p</i> = 0.01), and Clavien-Dindo grade ≥3a (<i>p</i> = 0.02) were significant factors for RFS in multivariate analysis. For non-SCC patients, neutrophil-to-lymphocyte ratio &gt;2.40 (<i>p</i> &lt; 0.01), SUVmax &gt;8.39 (<i>p</i> = 0.01), and pStage ≥II (<i>p</i> = 0.03) were significant factors for RFS in multivariate analysis. <b><i>Conclusion:</i></b> RFS did not differ significantly differently between SCC and non-SCC patients. It is necessary to perform more than segmentectomy and to avoid severe postoperative complications for SCC patients. SUV_max might be an adaptation criterion of adjuvant chemotherapy for patients with non-adenocarcinoma and non-SCC of the lung.